Maintaining aspirin use during kidney stone lithotripsy
Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study
This study is testing if continuing aspirin use during kidney stone treatment helps patients feel better and have fewer complications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT03437057 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and effectiveness of continuing acetylsalicylic acid (aspirin) treatment during extracorporeal lithotripsy (ECL) for patients with renal lithiasis. Patients over 18 years old, who are on a stable dose of aspirin, will be monitored before, during, and after the ECL procedure to assess pain levels, blood pressure, and any adverse reactions. The study aims to determine if maintaining aspirin therapy impacts the outcomes of the lithotripsy procedure, particularly in terms of stone clearance and hematoma formation.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with at least one renal stone requiring ECL who are currently taking aspirin as monotherapy.
Not a fit: Patients with bleeding disorders, those on anticoagulant therapy, or those requiring multiple ECL sessions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could allow patients to continue their antiplatelet therapy safely during kidney stone treatment, potentially reducing complications.
How similar studies have performed: While similar studies on antiplatelet therapy during surgical procedures exist, this specific approach to ECL and aspirin use is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Over 18 yo patients * Patients with 1 renal lithiasis (at least) requiring treatment with extracorporeal lithotripsy * Patients taking Kardégic 75 (monotherapy Exclusion Criteria: * Patients with known (or previously known) bleeding disorders on the pre-treatment assessment * Patients with anticoagulant therapy or other anti-aggregating therapy (eg Kardegic at 75mg, AVK, NACO, LMWH, HNF, P2Y12 inhibitor) * Patients with another contrindication to the ECL. * Patients with prescription of more than the outset 1 ECL session * Tutelage, curatorship, justice safeguarding, deprived of liberties, unaffiliated SS, impaired comprehension abilities, pregnant and lactating women.
Where this trial is running
Clermont-Ferrand
- CHU Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
Study contacts
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 04 73 75 49 63
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.